Virus and target cell evolution in human immunodeficiency virus type 1 infection

Immunologic Research

Volumn 21, Issue 2-3, 2000, Pages 253-258

  Mosier, D E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibody; CCR5 polymorphism; Coreceptors; Cytotoxic T lymphocyte; Human immunodeficiency virus

Indexed keywords

CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5;

ANTIGEN EXPRESSION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MACROPHAGE; MEMORY CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0033842733     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:21:2-3:253     Document Type: Article

References (38)

1. Transfer of a functional human immune system to mice with severe combined immunodeficiency
2. Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice
3. The scid mouse mutant
4. Human immunodeficiency virus infection of human-PBL-SCID mice
5. Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates
6. The envelope gp 120 gene of human immunodeficiency virus type 1 determines the rate of CD4-positive T-cell depletion in SCID mice engrafted with human peripheral blood leukocytes
7. Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice
8. The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes
9. Chemokine receptor CCR5 genotypeinfluences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice
10. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp 160 and recombinant gp 160
11. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp 120 CD4-binding site
12. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
13. Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism
14. The antiviral activity of HIV-specific CD8+CTL clones is limited by elimination due to encounter with HIV-infected targets
15. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
16. Quantification of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
17. In vivo migration and function of HIV-1-specific cytotoxic T cells
18. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
19. Dynamics of HIV-1 and CD4+ lymphocytes in vivo
20. HIV-1 antibody - Debris or virion?
21. Why do we not have an HIV vaccine and how can we make one?
22. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstratred by rapid selection of CTL escape virus
23. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
24. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells
25. How viruses hide from T cells
26. HIV type 1-specific helper T cells: A critical host defense
27. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication
28. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
29. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes
30. The V3 domain of the HIV-1 gp 120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
31. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes
32. In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5
33. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus
34. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
35. CCR5-delta 32 gene deletion in HIV-1 infected patients
36. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection
37. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression
38. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants